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The phosphatidylinositol 3-kinase (PI3K) signaling pathway regulates several cellular
processes and it’s one of the most frequently deregulated pathway in human tumors.
Given its prominent role in cancer, there is great interest in the development of inhibitors
able to target several members of PI3K signaling pathway in clinical trials. These drug can-
didates include PI3K inhibitors, both pan- and isoform-specific inhibitors, AKT, mTOR, and
dual PI3K/mTOR inhibitors. As novel compounds progress into clinical trials, it’s becoming
urgent to identify and select patient population that most likely benefit from PI3K inhibition.
In this review we will discuss individual PIK3CA mutations as predictors of sensitivity and
resistance to targeted therapies, leading to use of novel PI3K/mTOR/AKT inhibitors to a
more “personalized” treatment.
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INTRODUCTION
Over the past years, it has become widely accepted that can-
cer is a multistep genetic disease that arises by the activation of
specific oncogenes, inactivation of tumor suppressor genes, and
stochastic accumulation of genetic alterations driving tumor pro-
gression (Vogelstein and Kinzler, 2004). Despite the genetic and
epigenetic complexity observed in cancer, tumor growth and sur-
vival can be impaired by the inactivation of a single oncogene.
This phenomenon is called “oncogene addiction” (term coined
by Weinstein, 2000), and reveals a possible “Achilles heel” within
the cancer cell that can be therapeutically exploited (Weinstein,
2000, 2002). The hypothesis of oncogene addiction refers to the
observation that a tumor cell, despite several genetic alterations, is
dependent on a single oncogenic pathway responsible for sustain-
ing the malignant phenotype. An important implication is that
switching off this crucial pathway upon which cancer cells are
dependent should have negative effects on cancer while sparing
normal cells. Therefore pharmacological inhibition of this crucial
pathway cause an “addiction shock,” resulting in the blockade of
cell growth or in cell death (Sharma and Settleman, 2007; Janne
et al., 2009).
The “addiction paradigm” has been pharmacologically
exploited and drugs designed to specifically inhibit mutated pro-
teins have led to what is commonly known as “personalized
cancer medicine.” At present only a small subset of anticancer
therapies are administered based upon the genetic alterations
present in individual tumors (Martini et al., 2012). For example,
breast cancer patients with amplification/overexpression of the
human epidermal growth factor receptor (EGFR) 2 (HER-2) are
selectively sensitive to Trastuzumab and Lapatinib (Stern, 2012),
melanomas harboring BRAF V600E mutations to Vemurafenib
(Flaherty et al., 2010), non-small cells lung cancers (NSCLC) with
mutated EGFR to Erlotinib and Gefitinib (Pallis et al., 2011), and
KIT and PDGFRA mutant gastrointestinal stromal tumors (GIST)
to Imatinib (Antonescu, 2011).
The phosphatidylinositol 3-kinase (PI3K) signaling pathway
regulates several processes in normal cell such as survival, metab-
olism, and motility and it’s one of the most frequently deregulated
pathway in human cancer (Cantley, 2002; Samuels et al., 2004; Liu
et al., 2009a). Mutations and/or amplifications of the PI3K cat-
alytic subunits p110α (PIK3CA) and p110β (PIK3CB), the PI3K
regulatory subunits p85α (PIK3R1) and p85β (PIK3R2), the PI3K
effector AKT (AKT1) are often observed in cancer1. Moreover,
mutations, deletions, or epigenetic changes of negative regula-
tors of PI3K axis (Gewinner et al., 2009; Hollander et al., 2011),
such as phosphatase and tensin homolog (PTEN) and inositol
polyphosphate-4-phosphatase, type II (INPP4B), may alter sensi-
tivity to chemo- and targeted-therapies (Steelman et al., 2008; Kim
et al., 2012).
While class I is the most well characterized of the PI3K to
date, the family comprises other two groups; class II and class
III. Each class of PI3-kinase has unique preferences for phospho-
inositide substrates and produces specific lipid second messengers,
responding to a wide variety of signaling molecules.
Class II PI3Ks consists of three members named PI3K-C2α,
PI3K-C2β, and PI3K-C2γ. Unlike class I, they lack a regulative
subunit and appear to be monomers of high molecular weight,
predominantly associated with intracellular membranes (Falasca
et al., 2007). PI3K-C2α and PI3K-C2β have a broad tissue dis-
tribution and are almost ubiquitously expressed, while PI3K-C2γ
displayed a very restricted expression pattern, limited to liver, pan-
creas, and prostate (Kok et al., 2009). The precise nature of class II
substrates and lipid products is still debated. Class II members are
1www.sanger.ac.uk/cosmic
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thought to act similarly to class III mainly generating PtdIns(3)P
in vitro and in vivo (Falasca and Maffucci, 2007), nonetheless,
they can also produce PtdIns(3,4)P2 in vitro (Vanhaesebroeck
et al., 2010) and PI3K-C2α has been also reported to produce
PtdIns(3,4,5)P3 in vitro (Gaidarov et al., 2001). Class II PI3Ks
are activated downstream of different receptor types including
RTKs (EGFR and PDGFR) (Brown et al., 1999; Arcaro et al., 2000,
2002; Falasca and Maffucci, 2007) and GPCRs (Maffucci et al.,
2005). Several stimuli promote PI3K-C2α activation such as hor-
mones (insulin) (Brown et al., 1999), chemokines (Turner et al.,
1998), and cytokines (TNFα and leptin) (Ktori et al., 2003). Simi-
larly PI3K-C2β is activated by growth factor (EGF) (Arcaro et al.,
2002) and phospholipids (LPA) (Maffucci et al., 2005) while at the
present there are no study investigating PI3K-C2γ upstream acti-
vators. A recent study reported that PI3K-C2α has an essential role
in angiogenesis resulting in embryo lethality, impaired endothelial
cell signaling, and RhoA activation (Yoshioka et al., 2012).
The increasing understanding of the mechanisms underlying
the role of the PI3K pathway in tumorigenesis has encouraged
many pharmaceutical companies and academic laboratories to
focus their efforts on the development of inhibitors targeting the
PI3K signaling pathway at different levels.
In this review, we will discuss the challenges for the develop-
ment of novel inhibitors to target the PI3K signaling pathway
and the binary relationship between PI3K mutations in cancer
genotype and personalized medicine.
TARGETING PI3K SIGNALING PATHWAY IN CANCER
Since PI3K/AKT/mTOR axis has been classified among the most
frequently activated pathway in cancer, members of the cascade
represent an attractive target for cancer therapeutics (Miled et al.,
2007). The activation of the PI3K signaling pathway contributes
to several aspects of tumorigenesis as tumor development, pro-
gression, invasiveness, and metastasis formation. A number of
molecules targeting members of the PI3K axis have been devel-
oped and evaluated in preclinical studies as well as in clinical trials
(Figure 1). Based on pharmacokinetics properties and isoform
selectivity for the ATP binding site, PI3K inhibitors have been
classified into different groups (Table 1).
The first group encompasses inhibitors able to bind all class I
PI3Ks (pan inhibitors), and in particular PI3Kα, PI3Kβ, PI3Kγ,
and PI3Kδ. Wortmannin and LY294002, the first two prototype
PI3K inhibitors, represented for a long time a useful tool in the
study of PI3K function in cellular processes, given their effective-
ness at low concentration (nM). Nevertheless, given their poor
pharmacokinetic properties and lack of selectivity, these com-
pounds have limited their therapeutic potential. The availability
of the crystal structure of the p110 isoform-specific catalytic sub-
units gave a boost to the development of new PI3K inhibitors
(Vadas et al., 2011). Therefore, several novel compounds have
been further developed in order to improve pharmacokinetic pro-
files, to increase target specificity and to minimize toxicity. At the
present, several promising pan-PI3K inhibitors are under devel-
opment and evaluation in clinical trials for cancer therapy. These
molecules predominantly display cytostatic effects with conse-
quent G1 phase arrest in vitro and favorable anticancer effects
in vivo.
Lately, a second group of PI3K inhibitors has been developed
to overcome the toxicity displayed by the treatment with pan-
PI3K inhibitors. They are characterized by greater selective activ-
ity (isoform-specific) and several molecules are currently under
evaluation in preclinical and clinical studies.
On the other hand, since PI3K and mTOR share several struc-
tural similarities, many chemical compounds, under evaluation in
clinical trials, are able to inhibit both catalytic subunits. This third
group of inhibitors is termed “dual PI3K/mTOR” and they have
the advantage of inhibiting not only all class I isoforms but also
mTORC1 and mTORC2 thus having a strongest effectiveness in
switching off the PI3K signaling pathway.
Given the growing interest in inhibiting PI3K signaling path-
way, the drug development landscape is becoming increasingly
crowded and highly competitive, so that several pharmaceutical
companies, such as Novartis, Sanofi-Aventis, Roche/Genentech,
Bayer, and GlaxoSmithKline, are currently in competition to
FIGURE 1 | Schematic representation of PI3K pathway and sites of action of PI3K signaling pathway inhibitors in solid tumors and hematological
malignancies.
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Table 1 | PI3K inhibitors tested in preclinical and clinical models, genetic determinants of response, and open clinical trials described for each
compound.
Group Selectivity Compound Cancer type Genetic determinant
of response
Clinical trial status
I Pan-class I Class I PI3K GDC-0941
(Roche/Genentech)
Breast HER-2 amplification
PIK3CA mutations
I-II in breast,
non-Hodgkin’s
lymphoma, NSCLC
Melanomas, MM,
non-Hodgkin’s
lymphoma, NSCLC,
ovarian
–
BKM120
(Novartis)
Breast PIK3CA mutations I-II in breast CRC,
endometrial, GIST,
GBM, leukemia,
melanoma, NSCLC,
pancreatic, renal cell,
SCCHN, TCC
CRC, endometrial, GIST,
GBM, leukemia,
melanoma, NSCLC,
pancreatic prostate
–
PX866
(Oncothyreon)
Breast, CRC, MM,
NSCLC, pancreatic
prostate, ovarian
PIK3CA mutation, PTEN
loss
I-II in CRC, GBM,
NSCLC, SCCHN
BAY 80-6946
(Bayer)
Advanced solid cancers PIK3CA mutations I-II in advanced solid
cancers
II Isoform
specific
PI3Kα GDC-0032
(Roche/Genentech)
Solid cancers – I-II in solid cancers
PI3Kβ GSK2636771
(GlaxoSmithKline)
Advanced solid cancers – I-IIa in advanced solid
cancers with PTEN
deficiency
PI3Kγ and PI3Kδ IPI-145 (Infinity) Hematological
malignancies
– I-IIa in advanced
hematological
malignancies
PI3Kδ CAL-101 (Gilead
Sciences)
AML, CLL, Hodgkin’s
and non-Hodgkin’s
lymphoma, MCL
– I-II-III in AML, CLL,
Hodgkin’s and
non-Hodgkin’s
lymphoma, MCL, MM
III Dual
PI3K/mTOR
PI3K and mTOR BEZ235 (Novartis) Breast PIK3C2a mutation,
HER-2 amplification,
PTEN loss
I-II in breast, renal cell
Ovarian PIK3C2a mutation,
PTEN loss
bring their own inhibitors in the market. On the basis of these
considerations, we will describe and discuss results for the most
important PI3K inhibitors currently in clinical trial.
PI3K SIGNALING INHIBITION IN SOLID TUMORS
Several PI3K inhibitors have progressed through early clinical
safety and dose-escalation studies to phase I clinical trials on
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solid tumors. This allowed to define the treatment efficacy and to
identify patient population that will benefit from PI3K inhibitor
administration. Furthermore, a few number of compounds are
now progressing to phase Ib expansion cohort and phase II single
agent efficacy studies.
Several early reports were presented in the last 3 years revealing
safety and some preliminary activity data about the use of class I
PI3K and dual mTOR/PI3K inhibitors in patients.
GDC-0941 (GENENTECH-ROCHE)
GDC-0941 is a potent and selective oral inhibitor of class I PI3K
with activity against DNA-PK and also mTOR but at high concen-
trations (Folkes et al., 2008). GDC-0941 is currently under eval-
uation in several phase I clinical trials on patients with advanced
solid tumors, such as HER-2 positive metastatic breast cancer and
advanced NSCLC2. Several studies have documented the effects of
GDC-0941 on cell viability inhibition at submicromolar concen-
tration in several tumor types including glioblastoma, breast, and
prostate cell lines carrying specific alteration in the PI3K signal-
ing pathway. GDC-0941 exhibited excellent inhibition on MCF7,
T-47D, and SK-BR-3 breast derived cancer cell lines as a single
agent while in combination with rapamycin promotes apopto-
sis and down regulates cell cycle machinery components, such
as cyclin D1 (Zheng et al., 2012). In addition, the combinatorial
treatment of GDC-0941 and the Docetaxel in a panel of 25 breast
tumor cell lines (HER-2+, luminal, and basal subtypes) increases
the rate of apoptosis and enhances sensitivity to Docetaxel (Wallin
et al., 2012). The efficacy of combined GDC-0941 and chemo- and
targeted-therapies has also been demonstrated for other agents
such as Trastuzumab,Pertuzumab,and Docetaxel (Yao et al., 2009).
In NSCLC GDC-0941 synergizes also with the MEK inhibitor
(U0126) by promoting G0-G1 arrest and cell apoptosis (Zou et al.,
2012). Several clinical studies are currently evaluating the rela-
tive bioavailability, absorption, metabolism, excretion, and effects
of GDC-0941 in patient with advanced or metastatic tumors,
alone or in combination with Paclitaxel, Erlotinib, Carboplatin, or
Bevacizumab (see text footnote 2) GDC-0973 (MEK inhibitor).
Safety data about GDC-0941 monotherapy regimen have been
recently released. Phase I studies with a 3+ 3 dose-escalation
design showed that GDC-0941 is generally well tolerated at doses
below 450 mg every day (QD) and twice a day (BID) in patient
with advanced solid tumors. After treatment, signs of clinical activ-
ity have been reported, including a partial response (PR) by the
response evaluation criteria in solid tumors (RECIST) in a patients
with melanoma, ovarian, endocervical, and ER+/HER-breast can-
cer (Wagner et al., 2009; Moreno Garcia et al., 2011; Von Hoff et al.,
2011). Several side effects have been described after administra-
tion of GDC-0941 in about 10% of patients, in particular nausea,
diarrhea, fatigue, dysgeusia, and decreased appetite. In two dif-
ferent studies, the maximum tolerated dose (MTD) was enriched
at 450 mg with a dose limiting toxicities (DLT) of grade 3 (Gr)
macular rash and asymptomatic T -wave inversion in ECG, Gr3
thrombocytopenia, and Gr4 hyperglycemia (Moreno Garcia et al.,
2011; Von Hoff et al., 2011).
2www.clinicaltrials.gov
BKM120 (NOVARTIS)
BKM120 is an oral pyrimidine-derived pan-PI3K inhibitor with
potent activity at nanomolar concentrations against all class I PI3K
isoform while didn’t show any activity against other classes of PI3K
as well as mTOR. In vitro preclinical models showed that BKM120
has a strong anti-proliferative activity in more than 400 cancer
cell lines. The antitumor effects of BKM120 was also described in
several xenograft models of lung cancer (Fruman and Rommel,
2011) and metastatic HER-2+ breast cancer (Nanni et al., 2012).
Clinical data indicate that it is unlikely that BKM120 will achieve
exposures sufficient to significantly engage the off-target activ-
ity at tolerated doses and schedules, however careful dose range
selection is required to ensure specific targeting of PI3K signaling
pathway (Brachmann et al., 2012). Given its ability to penetrate the
blood-brain barrier, BKM120 may represent an attractive option
for the treatment of glioblastoma multiforme (GBM), the most
common and aggressive malignant primary brain tumor (Koul
et al., 2012). The first-in-human phase I dose-escalation study
investigated the MTD, safety, preliminary activity, and pharmaco-
dynamics of BKM120 (Bendell et al., 2012). The study reports that
BKM120 was well tolerated with a dose-dependent safety profile
and it describes related side effects, such as hyperglycemia, rash,
nausea, fatigue, and mood alterations. In particular hyperglycemia
is consistent with inhibition of PI3K signaling and has been
observed with other PI3K/mTOR/Akt pathway inhibitors. Distur-
bance of glucose homeostasis, as evidenced by hyperglycemia, was
more common at higher doses and may be attributed to BKM120
inhibition of p110. Pharmacodynamics data demonstrate a dose-
related inhibition of the PI3K signaling with significant decrease
in pS6 phosphorylation and decreased [18F]fluorodeoxyglucose
uptake. In another study, 77 patients with CRC, breast, lung, and
endometrial cancers received oral BKM120 in monotherapy once
daily (Call et al., 2010). PR were observed in two patients, a
triple negative breast cancer with KRAS and p53 mutation and
a ER+/HER− metastatic breast cancer carrying PIK3CA muta-
tions. At the same time, 58% of patients showed stable disease
(SD) response.
BAY 80-6946 (BAYER HEALTHCARE)
BAY 80-6946 is a potent pan-class I PI3K inhibitor with IC50
at sub-nanomolar concentration against PI3Kα (0.5 nM), PI3Kβ
(3.7 nM), PI3Kδ (0.7 nM), and PI3Kγ (6.4 nM) while it is inac-
tive against around 240 protein/lipid kinases and RTKs. BAY
80-6946 has shown antitumor activity against a panel of 140
tumor cell lines with an IC50 of 1–100 nM in about 60 tumor
cell lines. BAY 80-6946 displayed a strong activity of the PI3K
signaling pathway inhibiting AKT (Thr308 and Ser473) as well
as PRAS40, 4EBP1, and FOXOs phosphorylation in tumor cells
carrying PIK3CA activating mutations. BAY 80-6946 has been
demonstrated to induce apoptosis in a subset of PIK3CA mutant
tumors at concentrations lower that 100 nM in preclinical stud-
ies. The pharmacokinetics, pharmacodynamics, and MTD of BAY
80-6946 have been determined in a phase I escalation multicen-
ter study in patients with advanced solid tumors. Unlike other
PI3K inhibitors, BAY 80-6946 is administered intravenously as
1-h infusion once weekly for 3 weeks every month. Data deriv-
ing from phase I study revealed a MTD at 0.8 mg/kg and several
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side effects including hyperglycemia, fatigue, nausea, alopecia,
diarrhea, mucositis, dysgeusia, and grade 2/3 anemia. Moreover
a phase I study assessed safety, pharmacokinetics, and clinical
benefit in patients with advanced solid tumors, including breast,
endometrial, gastric cancer.
NVP-BEZ235 (NOVARTIS)
NVP-BEZ235 is a reversible, orally available, and selective inhibitor
of PI3K and TORC1/2. Several preclinical studies have already
demonstrate its efficacy in a variety of solid tumors such as
melanomas (Roper et al., 2011), breast (Brunner-Kubath et al.,
2011), CRCs (Manara et al., 2010; Roper et al., 2011), and sarcomas
(Manara et al., 2010). This compound suppresses cell proliferation,
induces G1 cell cycle arrest and promotes autophagy by inhibit-
ing the activity of AKT, S6K, S6, and 4EBP1 target proteins (Serra
et al., 2008; Cerniglia et al., 2012). In addition, data on glioma
xenograft demonstrate a reduction of the expression of the vascu-
lar endothelial growth factor (VEGF) on tumor vasculature, thus
suggesting an anti-angiogenetic effect for NVP-BEZ235 (Liu et al.,
2009b). Recently, NVP-BEZ235 also emerged as inhibitor of ATM
and DNA-PK at low concentration (100 nM). In this context, treat-
ment with NVP-BEZ235 may have significant radio sensitizing
effects with important implications in the rational design of clini-
cal trials (Mukherjee et al., 2012). At present, this molecule is under
evaluation in phase I/II clinical trials in patients with advanced
solid malignancies, including GBM (Salkeni et al., 2012), breast,
renal cell carcinoma (RCC), castration-resistant prostate cancer
(CRPC), endometrial carcinoma, and pancreatic neuroendocrine
tumors (see text footnote 2), alone or in combination with other
drugs such as Paclitaxel, Trastuzumab, Everolimus, and MEK162.
A 3+ 3 dose-escalation schedule with NVP-BEZ235 revealed tol-
erability at 600 mg BID dose and preliminary signs of clinical and
pharmacodynamic activity (Arkenau et al., 2012). In a phase IB
dose-escalation study, NVP-BEZ235 was administered in combi-
nation with Trastuzumab in HER-2+metastatic breast cancer (15
pts) with altered PI3K/PTEN status, showing an acceptable safety
profile and PR or SD in one and four patients respectively (Krop
et al., 2012). NVP-BEZ235 was also tested as a single agent or
Trastuzumab-combined with a novel formulation based on a solid
dispersion system (SDS) sachet (Peyton et al., 2011). The MTD for
the new formulated NVP-BEZ235 was determined as 1600 mg/day,
dose chosen for the ongoing phase II clinical trials. After treatment,
in 28 patients with advanced solid tumors, a stable response has
been evidence in a 40% of cases (Wen et al., 2012). Overall, these
studies display that NVP-BEZ235 is generally well tolerated and
the most common side effects include nausea, diarrhea, AST/ALT
elevation,and headache. DLT include fatigue,asthenia,Gr3 throm-
bocytopenia, and Gr3 mucositis (Peyton et al., 2011; Arkenau et al.,
2012; Wen et al., 2012).
PI3K SIGNALING INHIBITION IN HEMATOLOGICAL
MALIGNANCIES
Although the majority of PI3K inhibitors are under development
for the treatment of solid tumors, hematological malignancies also
represent a therapeutic area of interest, especially for isoform-
selective PI3K inhibitors. Constitutive activation of class I PI3K
isoform has been identified in high percentage of acute and chronic
leukemia. In addition, in some cases leukemias cell display overex-
pression of PI3Kα, PI3Kβ, and PI3Kγ. Conversely, the expression
of PI3Kδ has been found up-regulated in acute myelogenous
leukemia (AML) and in a subset of promyelocytic leukemia (APL).
AML comprises a heterogeneous group of tumors characterized
by uncontrolled proliferation of hematopoietic precursors thus
leading to accumulation of blast cells in the bone marrow. These
blasts are blocked in their differentiation program at different
stage of maturation. This blast accumulation causes a progres-
sive failure in the hematopoiesis process, which in turn leads to
anemia, neutropenia, and thrombocytopenia (Smith et al., 2004).
The standard therapeutic approach for the treatment of AML is
based on high-dose chemotherapy, nonetheless the prognosis of
AML remains poor with a 5-year survival rate in a 15–30% of
patients. A recent evidence demonstrated that up-regulation of
the PI3K/AKT/mTOR axis is a common feature in AML. Con-
sequently, several pan-PI3K and dual PI3K/mTOR inhibitors, in
particular BKM120 and BEZ235, are undergoing phase I clini-
cal development to assess safety, dose, and preliminary efficacy
in patients with advanced leukemias, relapsed or refractory acute
lymphoblastic and myelocytic leukemia (see text footnote 2).
Several studies demonstrated that treatment with the PI3Kδ
selective inhibitor, EC87114, inhibits AML cell proliferation with-
out affecting the proliferation of normal hematopoietic progenitor
cells (Sujobert et al., 2005; Billottet et al., 2006). In this context,
PI3Kδ inhibitors represent a promising therapeutic treatment for
AML without producing undesirable side effects that are con-
versely expected for other pan-PI3K inhibitors (Di Nicolantonio
et al., 2010). Additionally, since PI3Kδ is expressed in leukocytes
and plays a key role in B-cell signaling (Jou et al., 2002; Bilancio
et al., 2006), it represents an interesting target in B-cells malig-
nancies. Mice with deleted or kinase dead PI3Kδ exhibit B-cell
defects, such as lack of B1 lymphocytes, decreased number of
mature B-cell and impaired antibody production. The absence of
PI3Kδ in B-cell leads also to a reduction in AKT phosphorylation
and decreased PtdIns(3,4,5)P3 levels (Okkenhaug and Vanhaese-
broeck, 2003). All these data support the use of PI3Kδ inhibitors in
B-cell malignancies including the chronic lymphocytic leukemia
(CLL).
Given the increasing interest in inhibiting PI3Kδ for the
treatment of hematopoietic malignancies, several inhibitors are
currently under evaluation in preclinical and in clinical trials.
Presently, the most promising PI3Kδ inhibitor is represent by
CAL-101 (Calistoga Pharmaceuticals/Gilead Sciences), an orally
available selective inhibitor with an IC50 of 2.5 nM for PI3Kδ and
820, 565, 89 nM for PI3Kα, PI3Kβ, PI3Kγ respectively (Lannutti
et al., 2011). At the present, CAL-101 is undergoing in preclinical
and clinical development in a variety of lymphoid malignan-
cies thanks to its high selectivity. Phase I studies, on patients
with relapsed or refractory hematologic malignancies, including
non-Hodgkin lymphoma (NHL), CLL, and AML, revealed a very
favorable toxicity profile and pharmacokinetics during a week of
CAL-101 oral administration (Fruman and Rommel, 2011). The
predominant toxicity, caused by high serum transaminases, was
observed in 21% of patients at doses of 200 and 350 mg. However,
this side effect resulted to be reversible disappearing with a tempo-
rary discontinuation of the drug (Fruman and Rommel, 2011). In
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this study, 57 patients were treated with different dosages, corre-
sponding to 50, 100, 200, and 350 mg. Clinical responses were seen
at all dose levels resulting in 50% of reduction in lymphadenopa-
thy and around 6 months of stable disease. In a successive phase I
clinical trial CAL-101 was administered orally one or two times per
day for a cycle of 28 day in 54 patients with CLL. After treatment
with CAL-101, 26% of patients achieved a PR with 80% of patients
showing reduced lymphadenopathy by ≥50% (Di Nicolantonio
et al., 2010; Fruman and Rommel, 2011).
RELEVANCE FOR SELECTIVE INHIBITION OF CLASS II PI3Ks
Pharmacological inhibitors selectively targeting class II PI3Ks have
not been described yet. In particular, in vitro PI3K-C2α is refrac-
tory to inhibition by LY294002 and Wortmannin (Virbasius et al.,
1996; Domin et al., 1997), two very well-known PI3Ks inhibitors.
However, emerging evidence suggests that class II PI3Ks may have
crucial role in different types of tumor independently from class I
PI3K activity.
PI3K-C2α
RNAi-based silencing of PI3K-C2α in a large set of cancer cell lines
showed that this enzyme is crucially required for cancer cell sur-
vival in vitro (Elis et al., 2008). A small but significantly difference
in the DNA copy number and mRNA levels, was then reported
in vivo in 19 hepatitis B-positive hepatocellular carcinoma com-
pared with non-tumor tissues counterparts (Ng et al., 2009). The
PIK3C2A gene was also found to be up-regulated in breast cancer
stem-like cells characterized by increased tumorigenicity com-
pared with the normal counterpart (Zhou et al., 2007). Moreover, it
was reported that PI3K-C2α is directly down-modulated at a trans-
lational level by miR-30e-3p in DLD1 CRC cells (Schepeler et al.,
2012). In particular miR-30e-3p levels are significantly decreased
during early events of CRC carcinogenesis thus raising the possi-
bility that PIK3C2A gene may be up-regulated in the initial steps of
CRC onset. On the other hand, Yoshioka et al. (2012) showed that
PI3K-C2α has an essential role during angiogenesis process and in
vascular barrier function. After subcutaneous injection of Lewis
lung carcinoma (LLC) or B16-BL6 melanoma tumors, Pik3c2a
endothelial-restricted knock-out mice had reduced tumor vol-
umes/weights compared to control, suggesting that the in vivo
pro-angiogenetic function of PI3K-C2α is required for tumor
growth and maintenance. Further studies are needed to better
understand the role PI3K-C2α in tumor angiogenesis, however
designing of specific inhibitors targeting PI3K-C2α could repre-
sent a promising new anti-angiogenetic approach to arrest tumor
growth.
PI3K-C2β
An increasing number of studies described the involvement of the
gene PIK3C2B, encoding for PI3K-C2β, in cancer. Amplification
of PIK3C2B gene at 1q32 was reported in 6 out of 103 GBM tumors
and in 4 of these cases amplification correlates with PI3KC2B
mRNA over-expression (Knobbe and Reifenberger, 2003). Ampli-
fication of chromosomal region 1q32.1 (PIK3C2B\MDM4) was
also reported in around 8% of GBM tumor samples (Rao et al.,
2010) and in whole genome amplification analysis (Nobusawa
et al., 2010). On the other hand increased PI3K-C2β protein
levels significantly correlates with resistance to Erlotinib in GBM
thus suggesting that targeting of PI3K-C2β in resistant GBM may
represent a new therapeutic approach (Low et al., 2008).
To further support the hypothesis the role of PI3K-C2β in drug
resistance, a siRNA-based study reported that in a panel of kinases,
down regulation PIK3C2B is one of the Tamoxifen sensitizing
target in breast cancer cells (Iorns et al., 2009). Furthermore, over-
expression of PI3K-C2β significantly inhibited cisplatin-induced
apoptosis and cleavage of caspase-3 in esophageal squamous cell
carcinoma (Liu et al., 2011). Altogether these data suggest that
PI3K-C2βmay have a role in promoting resistance to chemothera-
peutic drugs and that interference with PI3K-C2β activity might be
a rational possibility for treatment of cisplatin-resistant esophageal
cancer patients. On the other hand, it has been recently showed that
down regulation of PI3K-C2β may specifically confer resistance
to leukemia cells to chemotherapy (thioguanine and mercaptop-
urine) (Diouf et al., 2011). Reduced levels of PI3K-C2β results in
increased degradation of MSH2, a DNA mismatch repair enzyme
involved in genomic integrity maintenance and drug resistance.
Although it’s becoming increasingly clear the involvement of PI3K-
C2β in chemotherapy resistance, further studies are needed to
clarify when the targeting of this enzyme could promote drug
sensitivity.
A recent study also reported that PIK3C2B gene single-
nucleotide polymorphisms (SNP) is associated to cancer risk sus-
ceptibility (Koutros et al., 2010). The authors examined the asso-
ciation between several SNPs in PI3Ks genes (PIK3CD, PIK3C2A,
PIK3R3, PIK3AP1, and PIK3C2B) and prostate cancer risk: among
the five genes, only PIK3C2B showed a cluster of SNPs related to
prostate cancer risk. PIK3C2B was also found to be significantly
mutated in a recent whole-exome sequencing screening in NSCLC
(Liu et al., 2012).
PI3K-C2γ
At the present very little is known about the role of PI3K-C2γ
in cancer. The chromosomal region 12p12, containing the human
PIK3C2G gene, is found significantly amplified in a subset of ovar-
ian cancer (Lambros et al., 2005) and in about 60% of pancreatic
ductal adenocarcinoma (PDAC) (Harada et al., 2008). Recently
bioinformatics analysis reported significative association between
PIK3C2G mutations and GBM related signaling pathways (Dong
et al., 2010). Another study also suggests a new mechanism through
which Bcr-Abl induces abnormal homing of leukemia cells by
reducing PI3K-C2γ expression (Yu et al., 2010). In this way, Bcr-
Abl is not only responsible for class I PI3K activation in cell
migration (Martelli et al., 2006) but also for PI3K-C2γ reduced
expression (Yu et al., 2010).
Altogether these data suggest that class II PI3Ks may exert addi-
tional or complementary role to class I PI3Ks in promoting cancer,
being involved in specific kind of tumors. The development of
selective inhibitors targeting class II PI3Ks may thus represent a
promising way of action, once the precise role of these enzymes in
cancer will be elucidated.
FUTURE PERSPECTIVES
As PI3K inhibitors progress into trials focusing on their clinical
efficacy, it is critical to identify genomic determinants of response
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and to stratify the patient population that will most likely benefit
from the treatment (Weigelt and Downward, 2012).
Historically rapalogs were the first PI3K pathway inhibitors
tested in clinical trials for cancer therapy and currently preclini-
cal models and early clinical data suggested that PIK3CA muta-
tions may predict sensitivity to treatment with PI3K/AKT/mTOR
inhibitors (Engelman et al., 2008; Ihle et al., 2009). In particu-
lar, it has been shown that patients with advanced malignancies
carrying PIK3CA pathway aberrations, showed high percent-
age of response to rapalogs and/or PI3K pan-inhibitor (Janku
et al., 2011b; Moroney et al., 2011). Moreover, PI3K pathway
aberrations due to PIK3CA mutations or PTEN loss correlate
with increase response to Doxorubicin, Bevacizumab, and Tem-
sirolimus in patients with advanced gynecologic and breast malig-
nancies (Moroney et al., 2011). Likewise, ovarian cancers with
coexisting PIK3CA and MAPK pathway mutations are sensitive to
PI3K inhibition, whereas CRC with the same repertoire of muta-
tions are resistant (Di Nicolantonio et al., 2010; Janku et al., 2011a,
2012). The identification of feedback loops leading to MAPK
activation, upon PI3K inhibition, underscores the potential of a
combined therapeutic approach with PI3K and MAPK inhibitors
(Carracedo et al., 2008; Laplante and Sabatini, 2012). According to
these findings, it has been proposed to incorporate predictive bio-
markers during the clinical drug development process from phase
I studies onward in order to enrich trials with patients more likely
to respond to a given targeted therapy and to increase the chances
of drug registration (Carden et al., 2010). For the guidance and
prioritization of predictive biomarker candidates in early clinical
trials, results derived from the study of preclinical models are of
primary importance to develop accurate companion diagnostic
tools.
CONCLUSION
In summary, although available dataset showed that a high per-
centage of tumors harboring PIK3CA will likely benefit from inhi-
bition of the PI3K pathway, a substantial proportion of patients
with PIK3CA activating mutations may be de novo resistant to
these agents. On the other hand, not all the patients with PIK3CA
mutations are sensitive to PI3K inhibitors and not all the patients
with wt PIK3CA/PTEN tumors are responsive. Moreover, while
the majority of the studies have restricted the analysis on the
PIK3CA and PTEN status, also occurring in other members of the
pathway, such as mTOR activating mutations, or INPP4B loss of
function, may play a role in the response to inhibitors. Therefore,
the possibility to target PI3K signaling pathway in cancer requires
deeper investigation, in order to identify additional biomarkers
and to improve therapeutic strategies in the clinic.
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